Reimagining psychoses: An agnostic approach to diagnosis

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 10-16

  Keshavan, Matcheri S ^a   Clementz, Brett A ^b   Pearlson, Godfrey D ^c   Sweeney, John A ^d   Tamminga, Carol A ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Pathophysiology; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMPA RECEPTOR AGONIST; CALCIUM CHANNEL BLOCKING AGENT; GLYCINE TRANSPORTER INHIBITOR; METABOTROPIC RECEPTOR AGONIST; NICOTINIC AGENT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DISORDER; CATATONIA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; DRUG TARGETING; ELECTROENCEPHALOGRAM; ENDOPHENOTYPE; EVIDENCE BASED MEDICINE; FAMILY HISTORY; HEBEPHRENIA; HISTORY OF MEDICINE; HUMAN; LABORATORY TEST; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; RELIABILITY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENDOPHENOTYPES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS;

EID: 84875917731     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.022     Document Type: Article

References (74)

1. Abrams R., Taylor M.A. Importance of schizophrenic symptoms in the diagnosis of mania. Am. J. Psychiatry 1981, 138(5):658-661.
2. Allardyce J., Suppes T., Van Os J. Dimensions and the psychosis phenotype. Int. J. Methods Psychiatr. Res. 2007, 16(Suppl. 1):S34-S40.
3. Allen A.J., Griss M.E., Folley B.S., Hawkins K.A., Pearlson G.D. Endophenotypes in schizophrenia: a selective review. Schizophr. Res. 2009, 109(1-3):24-37.
4. American, P., Association The dexamethasone suppression test: an overview of its current status in psychiatry. the APA Task Force on laboratory tests in Psychiatry. Am. J. Psychiatry 1987, 144(10):1253-1262.
5. Association A.P. The Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association.
6. Barabasi A.L. Network medicine-from obesity to the "diseasome". N. Engl. J. Med. 2007, 357(4):404-407.
7. Berrios G.E., Hauser R. The early development of Kraepelin's ideas on classification: a conceptual history. Psychol. Med. 1988, 18(4):813-821.
8. Bethune G., Bethune D., Ridgway N., Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J. Thorac. Dis. 2010, 2(1):48-51.
9. Biswal B.B., Mennes M., Zuo X.N., Gohel S., Kelly C., Smith S.M., Beckmann C.F., Adelstein J.S., Buckner R.L., Colcombe S., Dogonowski A.M., Ernst M., Fair D., Hampson M., Hoptman M.J., Hyde J.S., Kiviniemi V.J., Kotter R., Li S.J., Lin C.P., Lowe M.J., Mackay C., Madden D.J., Madsen K.H., Margulies D.S., Mayberg H.S., McMahon K., Monk C.S., Mostofsky S.H., Nagel B.J., Pekar J.J., Peltier S.J., Petersen S.E., Riedl V., Rombouts S.A., Rypma B., Schlaggar B.L., Schmidt S., Seidler R.D., Siegle G.J., Sorg C., Teng G.J., Veijola J., Villringer A., Walter M., Wang L., Weng X.C., Whitfield-Gabrieli S., Williamson P., Windischberger C., Zang Y.F., Zhang H.Y., Castellanos F.X., Milham M.P. Toward discovery science of human brain function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(10):4734-4739.
10. Bleuler E. Dementia Praecox, or the Group of Schizophrenias International Universities. New York 1950, 13-227.
11. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473(7346):221-225.
12. Carpenter W.T., Strauss J.S., Muleh S. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. Arch. Gen. Psychiatry 1973, 28(6):847-852.
13. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., de Vigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981, 38(1):15-22.
14. Craddock N., Owen M.J. The Kraepelinian dichotomy - going, going. but still not gone. Br. J. Psychiatry 2010, 196(2):92-95.
15. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Graf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerod A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Borresen-Dale A.L., Brenton J.D., Tavare S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
16. Dawes R.M., Faust D., Meehl P.E. Clinical versus actuarial judgment. Science 1989, 243(4899):1668-1674.
17. Decoster J., De Hert M., Viechtbauer W., Nagels G., Myin-Germeys I., Peuskens J., van Os J., van Winkel R. Genetic association study of the P300 endophenotype in schizophrenia. Schizophr. Res. 2012, 141(1):54-59.
18. Deisseroth K. Optogenetics and psychiatry: applications, challenges, and opportunities. Biol. Psychiatry 2012, 71(12):1030-1032.
19. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 2012, 169(11):1203-1210.
20. Ethridge L.E., Hamm J.P., Shapiro J.R., Summerfelt A.T., Keedy S.K., Stevens M.C., Pearlson G., Tamminga C.A., Boutros N.N., Sweeney J.A., Keshavan M.S., Thaker G., Clementz B.A. Neural activations during auditory oddball processing discriminating schizophrenia and psychotic bipolar disorder. Biol. Psychiatry 2012, 72(9):766-774.
21. Evans K., McGrath J., Milns R. Searching for schizophrenia in ancient Greek and Roman literature: a systematic review. Acta Psychiatr. Scand. 2003, 107(5):323-330.
22. Falret J.P. Mémoire sur la folie circulaire. Bull. Acad. Natl. Med. 1854, 19:382-415.
23. Fanous A.H., Neale M.C., Webb B.T., Straub R.E., O'Neill F.A., Walsh D., Riley B.P., Kendler K.S. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol. Psychiatry 2008, 64(2):121-127.
24. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160(4):636-645.
25. Greenwood T.A., Lazzeroni L.C., Murray S.S., Cadenhead K.S., Calkins M.E., Dobie D.J., Green M.F., Gur R.E., Gur R.C., Hardiman G., Kelsoe J.R., Leonard S., Light G.A., Nuechterlein K.H., Olincy A., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Freedman R., Braff D.L. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am. J. Psychiatry 2011, 168(9):930-946.
26. Griesinger W. Mental Pathology and Therapeutics 1845, Hafner Pub. Co., New York.
27. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69(8):776-786.
28. Hyman S.E. The diagnosis of mental disorders: the problem of reification. Annu. Rev. Clin. Psychol. 2010, 6:155-179.
29. Insel T.R. Rethinking schizophrenia. Nature 2010, 468(7321):187-193.
30. Insel T.R. Next-generation treatments for mental disorders. Sci. Transl. Med. 2012, 4(155):155ps119.
31. Insel T.R., Cuthbert B.N. Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol. Psychiatry 2009, 66(11):988-989.
32. Ivleva E.I., Morris D.W., Moates A.F., Suppes T., Thaker G.K., Tamminga C.A. Genetics and intermediate phenotypes of the schizophrenia-bipolar disorder boundary. Neurosci. Biobehav. Rev. 2010, 34(6):897-921.
33. Jager M., Haack S., Becker T., Frasch K. Schizoaffective disorder-an ongoing challenge for psychiatric nosology. Eur. Psychiatry 2011, 26(3):159-165.
34. Jaspers K. Allgemeine Psychopathology 1946, Springer Verlag, Heidelberg.
35. Jeste D.V., del Carmen R., Lohr J.B., Wyatt R.J. Did schizophrenia exist before the eighteenth century?. Compr. Psychiatry 1985, 26(6):493-503.
36. Kahlbaum K.L. Die Katatonie oder das Spannungsirresein 1874, Hirschwald, Berlin, Germany.
37. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 17(12):1174-1179.
38. Karayiorgou M., Flint J., Gogos J.A., Malenka R.C. The best of times, the worst of times for psychiatric disease. Nat. Neurosci. 2012, 15(6):811-812.
39. Kasanin J. The acute schizoaffective psychoses. 1933. Am. J. Psychiatry 1994, 151(6 Suppl.):144-154.
40. Keers R., Farmer A.E., Aitchison K.J. Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. Psychol. Med. 2009, 39(8):1231-1235.
41. Kendell R., Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am. J. Psychiatry 2003, 160(1):4-12.
42. Kendell R.E., Cooper J.E., Gourlay A.J., Copeland J.R., Sharpe L., Gurland B.J. Diagnostic criteria of American and British psychiatrists. Arch. Gen. Psychiatry 1971, 25(2):123-130.
43. Kendler K.S. Toward a scientific psychiatric nosology. Strengths and limitations. Arch. Gen. Psychiatry 1990, 47(10):969-973.
44. Keshavan M.S., Tandon R., Boutros N.N., Nasrallah H.A. Schizophrenia, "just the facts": what we know in 2008 part 3: neurobiology. Schizophr. Res. 2008, 106(2-3):89-107.
45. Keshavan M.S., Morris D.W., Sweeney J.A., Pearlson G., Thaker G., Seidman L.J., Eack S.M., Tamminga C. A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: the Schizo-Bipolar Scale. Schizophr. Res. 2011, 133(1-3):250-254.
46. Kraepelin E. 1899/1921, Manic-depressive Insanity and Paranoia E&S Livingstone, Edinburgh.
47. Lichtenstein P., Yip B.H., Bjork C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373(9659):234-239.
48. Liu J., Kiehl K.A., Pearlson G., Perrone-Bizzozero N.I., Eichele T., Calhoun V.D. Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response. Neuroimage 2009, 46(3):809-816.
49. Loscalzo J., Kohane I., Barabasi A.L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 2007, 3:124.
50. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44(1):5-21.
51. McClintock S.M., Freitas C., Oberman L., Lisanby S.H., Pascual-Leone A. Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol. Psychiatry 2011, 70(1):19-27.
52. Meda S.A., Gill A., Stevens M.C., Lorenzoni R.P., Glahn D.C., Calhoun V.D., Sweeney J.A., Tamminga C.A., Keshavan M.S., Thaker G., Pearlson G.D. Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol. Psychiatry 2012, 71(10):881-889.
53. Meda S.A., Narayanan B., Liu J., Perrone-Bizzozero N.I., Stevens M.C., Calhoun V.D., Glahn D.C., Shen L., Risacher S.L., Saykin A.J., Pearlson G.D. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort. Neuroimage 2012, 60(3):1608-1621.
54. Meehl P.E. Bootstraps taxometrics. Solving the classification problem in psychopathology. Am. Psychol. 1995, 50(4):266-275.
55. Meyer A. Psychobiology: A Science of Man 1957, Charles C. Thomas, Springfield.
56. Muller N., Dursun S.M. Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now?. J. Psychopharmacol. 2011, 25(6):713-714.
57. National Research Council (U.S.).Committee on A Framework for Developing a New Taxonomy of Disease Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 2011, National Academies Press, Washington, D.C.
58. Prasad K.M., Keshavan M.S. Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"?. Schizophr. Bull. 2008, 34(4):774-790.
59. Prasad K.M., Eack S.M., Keshavan M.S., Yolken R.H., Iyengar S., Nimgaonkar V.L. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr. Bull. 2012, (Epub ahead of print).
60. Robins E., Guze S.B. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am. J. Psychiatry 1970, 126(7):983-987.
61. Rzhetsky A., Wajngurt D., Park N., Zheng T. Probing genetic overlap among complex human phenotypes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(28):11694-11699.
62. Sedler M.J. The legacy of Ewald Hecker: a new translation of "Die Hebephrenie". Translated by Marie-Louise Schoelly. Am J Psychiatry. 1985142(11):1265-1271.
63. Schneider K. Clinical Psychology 1959, Grune and Stratton, New York.
64. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
65. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., Goldhirsch A., Untch M., Mariani G., Baselga J., Kaufmann M., Cameron D., Bell R., Bergh J., Coleman R., Wardley A., Harbeck N., Lopez R.I., Mallmann P., Gelmon K., Wilcken N., Wist E., Sanchez Rovira P., Piccart-Gebhart M.J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
66. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria. Psychopharmacol. Bull. 1975, 11(3):22-25.
67. Strauss J.S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr. Bull. 1974, (11):61-69.
68. Sullivan P.F. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010, 68(2):182-186.
69. Tandon R. The nosology of schizophrenia: toward DSM-5 and ICD-11. Psychiatr. Clin. North Am. 2012, 35(3):557-569.
70. Tandon R., Maj M. Nosological status and definition of schizophrenia: some considerations for DSM-V and ICD-11. Asian J. Psychiatry 2008, 1(2):22-27.
71. Trusheim M.R., Berndt E.R., Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6(4):287-293.
72. van Praag H.M. Kraepelin, biological psychiatry, and beyond. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):29-32.
73. Waltman P., Pearlman A., Mishra B. Interpreter of maladies: redescription mining applied to biomedical data analysis. Pharmacogenomics 2006, 7(3):503-509.
74. Yang J.C., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., Yu C.J., Chang G.C., Ho C.L., Sequist L.V., Dudek A.Z., Shahidi M., Cong X.J., Lorence R.M., Yang P.C., Miller V.A. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012, 13(5):539-548.